Given the established efficacy profile of anti-IL6 inhibitors in challenging cases of RA, particularly for those with inadequate responses to anti-TNF agents or systemic inflammatory manifestations, it is reasonable to assume that these agents were reserved for or preferred in patients presenting with a greater disease burden, older age, or more significant functional decline [33]. This evidence concerns the gene IL6 and rheumatoid arthritis.